Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Top Cited Papers
Open Access
- 28 October 2020
- journal article
- research article
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
Abstract
Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric VSV/SARS-CoV-2 reporter virus, we show that functional SARS-CoV-2 S protein variants with mutations in the receptor-binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Notably, SARS-CoV-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequencies in circulating SARS-CoV-2 populations. Finally, the emergence of antibody-resistant SARS-CoV-2 variants that might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of antibody combinations that target distinct neutralizing epitopes.Keywords
All Related Versions
Funding Information
- National Institute of Allergy and Infectious Diseases (R37AI64003)
- National Institute of Allergy and Infectious Diseases (R01AI078788)
- National Institute of Allergy and Infectious Diseases (P01AI138398-S1)
- National Institute of Allergy and Infectious Diseases (R01AI091707-10S1)
- George Mason University (Fast Grant)
- European ATAC Consortium (EC101003650)
- National Institutes of Health (UL1 TR001866)
- National Institute of Allergy and Infectious Diseases (2U19AI111825)
- G. Harold and Leila Y. Mathers Charitable Foundation
- Robert S. Wennett Post-Doctoral Fellowship
- Shapiro-Silverberg Fund (Advancement of Translational Research)
- Howard Hughes Medical Institute (Investigators)
- National Institute of General Medical Sciences (T32GM007739)
This publication has 49 references indexed in Scilit:
- Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoirJournal of Experimental Medicine, 2019
- Mapping the Evolutionary Potential of RNA VirusesCell Host & Microbe, 2018
- Data, disease and diplomacy: GISAID's innovative contribution to global healthGlobal Challenges, 2017
- Viral quasispeciesVirology, 2015
- Variation in RNA Virus Mutation Rates across Host CellsPLOS Pathogens, 2014
- CoronavirusesRNA Biology, 2011
- Correlates of Protection Induced by VaccinationClinical and Vaccine Immunology, 2010
- Rates of evolutionary change in viruses: patterns and determinantsNature Reviews Genetics, 2008
- The evolution of RNA viruses: A population genetics viewProceedings of the National Academy of Sciences, 2000
- Immunoglobulins in the lung.Thorax, 1986